



**AGING
ANALYTICS
AGENCY**

FemTech Healthcare Landscape Overview 2019

*Longevity and Preventive Medicine
Special Case Study*

Executive and Infographic Summary

FemTech Healthcare Landscape Overview Q1 2019

Longevity and Preventive Medicine Special Case Study

Executive Summary 3

FemTech Landscape Overview 19

FemTech Healthcare Sector Overview 35

FemTech Preventive Medicine Sector Overview 45

FemTech Longevity Sector Overview 55

FemTech Media and Conferences 65

APPENDICES AND PROFILES

FemTech Healthcare Companies 73

FemTech Preventive Companies 125

FemTech Longevity Companies 167

FemTech Healthcare Investors 199

FemTech Preventive Investors 352

FemTech Longevity Investors 495

FemTech Healthcare Influencers 572

FemTech Healthcare Journalists 604

FemTech Healthcare Conferences 616

Disclaimer 635

FemTech Healthcare Landscape Overview Q1 2019

Companies - 120
Investors - 335

Preventive
Medicine

FemTech
Healthcare

Investors

Companies

FemTech
Healthcare
Landscape
Overview
Q1 2019



AGING
ANALYTICS
AGENCY

DEEP
KNOWLEDGE
ANALYTICS

LONGEVITY
INTERNATIONAL

FemTech
Longevity

30 FemTech Healthcare Influencers



Jill Angelo
Geneve



Elina Berglund
Natural Cycles



Anne Boden
Starlingbank



Tania Boler
Elvie



Kate Bolton
CommsForGood



Ghela Boskovich
FemTech Global



Marija Butkovic
Women of Wearables



Judith Campisi
Buck Institute for Research on Aging



Lina Chan
Adia Health



Nicole Dahlstrom
FemTech Collective



Alexandra Fine
Dame Products



Elizabeth Gazda
Embr



Robin Farmanfarmaian
RF



Molly Hayward
Cora



Angie Lee
The Angie Lee Show



Janet Lieberman
Dame Products



Liz Lumley
Rainmaking



Elena Medo
Medolac



Devie Mohan
Burnmark



Kate Moyle
Pillow



Nuala Murphy
Moment Health



Elena Mustatea
Bold Health



Anastasia Georgievskaya
Haut.AI



Katherine Ryder
Maven Clinic



Maria Molland Selby
ThinX



Nicole Shanahan
ClearAccessIP



Tammy Sun
Carrot



Ida Tin
Clue



Jennifer Tye
Glow




Adriana Vazquez
Lilu

15 FemTech Healthcare Conferences



AWE USA 2019



Hacking Female Health



FemTech 2019 - What's Next?



FemTech Women's March Meeting



FemTechNet Network Gathering



Fertility Conference 2020



Rejuvenation Biotechnologies



Reproductive Health Venture Fair



Undoing Aging



Wearables & Ethics




Wired Health



Women in Tech Festival 2019



Women of Silicon Roundabout



Women of Silicon Valley



Women of Wearables Tech Show

10 FemTech Healthcare Journalists



Forbes

NewScientist

Forbes

STRICTLY|VC

Nicole Dahlstrom

Reenita Das

Jessica Hamzelou

Tanya Klich

Connie Loizos



Forbes

THE RINGER



Mary Loritz

Bérénice Magistretti

Molly McHugh

Sarah Dubow

Jonathan Symcox

FemTech Healthcare	FemTech Preventive Medicine	FemTech Longevity
Address health conditions which do not necessarily progress with age.	Address health conditions that do not necessarily progress with age.	Address health conditions that progress with age.
Palliative approach is sufficient.	Palliative approach.	Use disruptive approaches discussed in previous reports (technologies such as geroscience, regenerative medicine, etc).
No need to influence core aging processes.	Does not affect core aging processes.	Directly linked to biological aging.
		

Top FemTech Longevity Companies

Top FemTech Companies

Investors

1		Jumpstart Fertility		StartUp Health
2		Centre for Female Reproductive Longevity and Equality at the Buck Institute for Research on Aging		Portfolia
3		Ovascience		Puget Sound Venture Club
4		Center for Advanced Reproductive Technology		Golden Seeds
5		Inovium Rejuvenation		Alliance of Angels
6		Haut.AI		Houston Angel Network
7		New Hope Fertility Center		Hunt BioVentures
8		Center for Human Reproduction		Cycad Group
9		Joy Lux		RA Capital Management
10		Genneve		General Catalyst

Top 15 Mobile Healthcare Applications Used by Women



Samsung Health

Tracks activity, nutrition, stress data, heart rate, and sleep, and delivers insights based on user progress.



Lifesum - Diet Plan, Macro Calculator & Food Diary

Diet plan, food diary, macro calculator, calorie counter, and healthy recipes.



MyFitnessPal

Calorie counter and diet tracker.



Calorie Counter by FatSecret

Calorie counter, weight loss and dieting app.



Calm - Meditate, Sleep, Relax

App for meditation and sleep.



BetterMe: Weight Loss Workouts

Builds meal and workout plans.



Female Fitness - Women Workout

Female fitness app.



Pedometer

Records the number of steps you have walked, displays the number of calories you have burned, distance, and walking time.



Eve Period Tracker - Love, Sex & Relationships App

Period and ovulation tracker with love, sex, and relationships tips.



Maya - Period, Fertility, Ovulation & Pregnancy

Tracks periods, related symptoms, mood swings, pregnancy, and your overall health.




Period Tracker - Period Calendar

Tracks periods, cycles, ovulation, and the chance of conception.



Period Tracker - Period Calendar

Period and PMS symptoms tracker, helpful pregnancy app, accurate ovulation calendar, and fertility calculator.



Period Tracker Clue: Ovulation, Period Tracker App

Period tracker and ovulation calculator.



Waterbalance

Tracks water balance based on different parameters.




YAZIO Calorie Counter, Nutrition Diary & Diet Plan

Tracks activity, nutrition, and helps lose weight.

The Positioning of Women's Health Products and Services

Since the main areas of concern for the healthcare industry regarding women are centered on access to affordable healthcare, maternal and child care, family planning and fertility, management of chronic diseases, and elderly care, most Femtech applications therefore revolve around key women health issues, such as reproductive and maternal health, general health, and wellness, the latter of which includes mental health, chronic diseases, and communicable diseases.



FemTech encompasses a great many innovations dealing with menstruation, ranging from relatively simple innovations such as period proof-underwear to more advanced digital solutions such as **menstrual cycle tracking** and **period monitoring**.

 <p>Period Tracker, My C Simple Design Ltd.</p> <p>★★★★★</p>	 <p>Period Tracker Flo, F Flo Health, Inc.</p> <p>★★★★★</p>	 <p>Period Calendar, Cy SimpleInnovation</p> <p>★★★★★</p>	 <p>Period Tracker, Ovul Leap Fitness Group</p> <p>★★★★★</p>	 <p>Period Tracker Clue BioWink GmbH</p> <p>★★★★★</p>	 <p>Period Calendar Amila</p> <p>★★★★★</p>	 <p>Ovulation Calculator PINKBIRD</p> <p>★★★★★</p>	 <p>Period and Ovulation SMSROBOT LTD (Auto C</p> <p>★★★★★</p>	 <p>Maya - Period, Fertil Plackal Tech</p> <p>★★★★★</p>
 <p>Period Tracker Leap Fitness Group</p> <p>★★★★★</p>	 <p>Period Tracker GP International LLC</p> <p>★★★★★</p>	 <p>Menstrual Calendar witz</p> <p>★★★★★</p>	 <p>Period Tracker & W Living Better</p> <p>★★★★★</p>	 <p>Period Tracker Dora YY Huang</p> <p>★★★★★</p>	 <p>Period Tracker MIA Mobapp Development L</p> <p>★★★★★</p>	 <p>Ovulation Calendar Leap Fitness Group</p> <p>★★★★★</p>	 <p>Ladytimer Ovulation Vipos Apps</p> <p>★★★★★</p>	 <p>My Menstrual Diary Baskaran Arunasalam</p> <p>★★★★★</p>
 <p>My menstrual calcul Quoidonc.com</p> <p>★★★★★</p>	 <p>Period tracker. Ovul Wachanga</p> <p>★★★★★</p>	 <p>Period App Cherry - Health Group: Fitness, E</p> <p>★★★★★</p>	 <p>حاسبة الدورة الشهرية OneMena</p> <p>★★★★★</p>	 <p>WomanLog Period Pro Active App</p> <p>★★★★★</p>	 <p>Menstrual & Ovulation Grupo Precedo</p> <p>★★★★★</p>	 <p>Woman diary (calendar DSN Inc.</p> <p>★★★★★</p>	 <p>Period Calendar Pro Simple Design Ltd.</p> <p>★★★★★ \$4.46</p>	 <p>Menstrual Calendar witz</p> <p>★★★★★ \$3.35</p>

Before September 2016, nobody had even heard the term.....and yet it describes a market predicted to be worth \$50bn by 2025.

FemTech refers to the emerging range of digital technologies focused specifically on women's health.

It consisting largely of wearable devices and smartphone interfaces,, connected medical devices, and hygiene products. These products, platforms, and techniques are geared towards widening female access to healthcare on a global scale, empowering as well as educating women.

Femtech is an offshoot of HealthTech, in the sense that it relies on preventive or analytic systems to monitor and maintain health, but represents a major departure from the traditional tech scene that has been dominated by male-oriented product designs and applications. The term was coined by Ida Tin, founder and CEO of Clue, an app which enables users to share information regarding menstrual cycles with partners, family, and friends. Tin believes that connected mobile technology is the future of female health.

In 2017 we saw a huge expansion of the Femtech movement. It was the year in which startups, VCs, press, activists, and nonprofits began to converge on the sector, cementing its uniqueness and identity. This was the year in which Femtech firms 'The Flex Company' and 'Glow' hosted a dinner in Washington D.C. the night before the Women's March to discuss this issue. Attendees included Femtech startups such as Celmatix, Cora, and Clue, female-oriented nonprofits such as Camions of Care and Support the Girls, activists, lobbyists, lawyers, and authors focused on female health.

But why does FemTech suddenly matter now?

According to Frost & Sullivan, women are 50% of the population but now control 80% of healthcare decisions. Moreover, women in the workforce spend 29% more per capita on healthcare than their male peers, and they're 75% more likely to use digital tools to track their health. Even when health insurance companies fail them, women are willing to use contraceptive and fertility apps, subscription birth control, and other femtech tools to meet their needs.

So FemTech matters because women's voices are becoming more influential.

J. Walter Thompson Intelligence states that it may have something to do with the rise of fourth-wave feminism: *"Long seen as taboo, the rise of fourth-wave feminism is encouraging women to talk about their vaginas and vulvas like never before, whether that's to do with periods, health, sex, and masturbation or well-being."*

So it should come as no surprise that women care about their health and are willing to try out these new solutions. Femtech clearly isn't just a novelty or fad: It's a movement. In our digital age, it's becoming a way of life for women across the globe.

But why are all of these innovations happening now? According to Tania Boler, CEO of Elvie (see [appendix: companies](#) and [appendix: influencers](#)): *"The rise of so-called Femtech is part of three larger movements currently going on: The feminist surge (as well as the #metoo movement); the huge technological revolution that's yielding instant personal data; and the paradigm shift in health, in which the patient/doctor paradigm is giving way to individual control of our own health."*

In a lot of cases, these products are being developed by people who will actually use them. A similar shift occurred in the sex toy industry in which made a major shift from being a male-dominated industry that primarily used cheap materials to one where many of the best brands are either founded by women or have women on their design teams and they are using the latest advancements in technology.

In the past two decades, a greater number of educated women have entered the workforce each year. Working women in the US earn a total of US \$4.3 million annually and represent about 50% of the workforce in the country. In the US and Europe, women account for almost 60% of the college students, indicating that the future will likely see more qualified women in the workforce than men. The global economy will have a 15% increase in global GDP if the employment rates are equal for both men and women. With the influence women have on global spending, the economy, in developed countries at least, is turning into a SHEconomy.

Yet, women have access to few resources to help them succeed at work.

There is a large opportunity for women themselves to step into digital health and enable detection of early signs of stress and health predictors that can help women take note of their condition and make lifestyle decisions to manage their health better.

Now is also the time when technology has the potential to break the cost barrier faced by women in developing countries, often more than men or their counterparts in developed countries, because they either endure or hide their condition or do not have the financial independence to make health decisions. This is particularly relevant for conditions like breast cancer or cervical cancer, which women are unable to diagnose quickly, often due to lack of effective enforced screening programs.

Women in developing countries are more likely to drop from the workforce due to inadequate support for home and childcare, leaving them financially dependent and often not in control of their decisions, even on aspects like healthcare. In these conditions, clinically effective, low-cost Femtech applications can impact a large number of women.

Female Economic Power will Outpace that of Leading Nations

Female-powered earnings are poised to outpace the economies of the world's biggest nation in the next 5 years. Tapping into this growth and understanding women as customers is essential to corporate prosperity.

Female Earnings, Global, 2014-2020

China's GDP (Normal) in 2020

The United States GDP (Normal) in 2020



The Female economy will be bigger than the economy of China and the United States by 2020.

Women-owned units will represent over 40% of registered business worldwide by 2020.

Equal male and female employment rates would boost the economy of developed nations by 5-9%. In emerging nations this could add an additional 30% to the economic output

37% of High Networth Individuals (HNIs) will be women globally controlling nearly 20% of total wealth.

In Africa, women constitute 70% of the workforce for total crop production.

Room for Growth

Yet, despite having such a big potential, the Femtech industry currently attracts only 1.4% of the aggregate capital that flows into healthcare, according to Masterson. Also, a big number of healthcare venture capitalists have yet to invest in Femtech.

Investment in Femtech is certainly growing, but it's at a shockingly slow pace, considering its potential. The U.S. Food and Drug Administration has cleared more and more femtech applications and products over the past few years, so companies are definitely aware of the buying power of women. However, companies and funders need to recognize the growing power and potential of this new growing category, too.

And there are signs of future growth on the horizon.

Just five years ago, the share of global funding for the femtech sector would barely manage to reach \$100 million. Currently, the femtech industry is set to see a huge increase to more than \$400 million – the largest amount of funding the industry has ever received.

Startups targeting women's healthcare have multiplied in recent years, spurred in part by PayPal co-founder Max Levchin's launch of fertility tracking app Glow in 2013, which saw early funding from high-profile VCs such as Andreessen Horowitz and Founders Fund.

Today, we see a number of startups offering fertility tracking apps, as well as startups focused on egg freezing and fertility treatments, women-only clinical care, and even subscription tampons. Top-tier VCs have entered the field, as well. Kleiner Perkins, for example, has backed fertility platform Progyny (\$49M in total disclosed funding), while NEA has backed sexual wellness startup Nuelle (\$23M in total disclosed funding). Most recently on 1/26/17, reproductive therapeutics startup Obseva announced pricing for a planned IPO.

“Investors don’t take women’s tech as seriously as they need to. But given that the consumer need is so big, it is going to hit them on the head at some point and I feel this is starting to happen. We’re still at the beginning of changing the conversation, but it is happening and there is plenty of room for innovation in this space which means more innovative products and investment opportunity.”

– Tania Boler, co-founder and CEO of Elvie



In February 2019, Procter & Gamble (P&G) announced its acquisition of This is L., a period care startup that manufactures organic pads and tampons. This is L. was founded in 2011 by Talia Frenkel, a former photojournalist who has worked with the United Nations and the Red Cross. The company has a one-for-one give back model: for every product sold, one is made available to another woman.

The period care space in particular has grown considerably over the past few years, with freshly minted startups like This is L. making a name for themselves by being more transparent about their manufacturing process. According to its website, L.'s organic products are free of any pesticides, chlorine, fragrances or dyes.

Other organic period care startups include Cora, Lola and Freda, which are also all actively contributing to end period poverty through various initiatives.

C O R A
Cora
Funding: \$6M
Investors: Harbinger Ventures

L O L A
Lola
Funding: \$35.2M
Investors: Spark Capital, Lerer Hippeau Ventures, BoxGroup

L.
This is L.
Funding: \$120K
Investors: Y Combinator, Fusion Fund

A decade ago, just \$23 million worth of venture capital was invested in the global FemTech industry.

That figure grew steadily to \$334 million in 2015. In 2017, VC investors participated in femtech deals totaling \$354 million. In 2018 it was \$391.5 million across 36 deals.

Over the last decade, 365 VC investors have participated in deals in FemTech.



The top 10 most active investors in the FemTech sector in past 10 years are:

- Y Combinator
- Arboretum Ventures
- BoxGroup
- NEA
- Founders Fund
- Astia Angels
- InterWest Healthcare Partners
- Chrysalis Ventures
- Catalyst Health Ventures
- Union Square Ventures

By HER For HER



Plan or prevent pregnancy with Dot's algorithm.



The rise of Femtech has coincided with a “second phase” of wearables with more focus on the integration of wearables and health data. The question that remains is what to do with this data, the answer may lie in long-term health tracking.

For example, medical trials in the US have only been allowed to include women since 1993, so there is a lack of female health data that could be improved using femtech wearables. There are barriers to entry in the femtech market; companies receiving high levels of funding almost always have multiple patent families.

A new collaboration between Clue and Fitbit announced in late February 2018 will allow women to start collecting their health data on their wrists. The availability of Clue on Fitbit’s Ionic sport watch is the first period tracking app to be compatible with the Fitbit OS. Based on the internal pilot study, Clue has already been able to spot a correlation with spikes in heart rate and ovulation.


Ida Tin, CEO and Co-Founder, Clue, and originator of the term ‘FemTech’, commented that *“One of the exciting things about merging tech and female health is that we start having exciting amounts of data.”*

In this regard also therefore, Femtech is still very much a growing space, with companies such as Elvie, the developer of a pelvic floor strengthening product, posting growth of 50 percent quarter-over-quarter and hinting at new product launches. There is space for new innovations and start-ups to grow in years to come. One area that we have identified having a need for innovation is products aimed at menopause and post-menopausal women. There is still plenty of opportunity for growth and innovation in femtech.

Timeline:  fitbit in Pink Through the Years



FemTech market share



*Digital health startups raised \$3.5 billion in the first two quarters of 2016 (full 2016 data not yet available). Startups in a women's health sector raised over \$1.1B in total since 2014.

The report is structured in order to introduce readers to the major trends and players in the industry via several infographic MindMaps, so that the reader can quickly ascertain the report's major analytical findings and conclusions. It provides a framework for better structure readers' understanding of the entire FemTech field. It then dives into greater detail in each successive chapter, focusing on specific areas.

FemTech Landscape Overview describes the FemTech industry in its 2019 state, using our standard mindmap and succinct infographics

The **FemTech Healthcare** chapter covers FemTech which addresses health conditions that do not necessarily progress with age. These companies take a palliative approach and do not influence core aging processes.

The **FemTech Preventive** chapter covers FemTech which addresses health conditions that do not necessarily progress with age. These companies take a preventive approach and do not interfere with core aging processes.

The **FemTech Longevity** chapter covers FemTech which addresses health conditions that progress with age. These companies use disruptive approaches discussed in previous reports (technologies such as geroscience, regenerative medicine, etc), and act upon processes closely linked to biological aging.

Our appendix offers comprehensive profiles of the **companies, investors, influencers,** and **conferences** comprising the industry in its current state:

- **FemTech Healthcare Companies**
- **FemTech Preventive Medicine Companies**
- **FemTech Longevity Companies**
- **Femtech Healthcare Investors**
- **Femtech Healthcare Influencers**
- **Femtech Healthcare Journalists**
- **Femtech Healthcare Conferences**

Femtech is a burgeoning, upstart industry with a rapidly increasing public profile, increasingly diverse applications, increasing investor attention, set to have an increasing share of the capital directed at healthcare.

The story of FemTech is apparent from an examination of the sectors of the industry -- **General, Preventive, and Longevity** -- in that order.

In fact, these three categories, although they may appear arbitrary at first, mark the stages of the same paradigm shift that this report series has sought to document for years now: The shift toward increased disruption, away from palliative solutions and toward comprehensive, preventive engineering solutions, made possible by a series of **synergies**.

The **FemTech Healthcare chapter**, describes how FemTech has emerged from **current synergies** between the traditional decades-old solutions to female health, and more recent digital and biomedical advances.

The **FemTech Preventive Medicine chapter** describes how FemTech, in lockstep with the other technologies described in this report series, has undergone a shift from treatment to prevention through advanced prognostics.

And finally, the **FemTech Longevity chapter** alludes briefly to the **incipient future synergy** between FemTech and the broader Longevity industry described throughout our previous reports, and charts the likely ways in which the FemTech Longevity sector will diversify in the coming years, moving more and more into the real of concrete preventive medicine focused on maximizing healthy female Longevity.

A tech sector focusing exclusively on female health will inevitably have some special significance for those areas of declining health which are inextricable from the aging process, such as the effects of menopause.

As such FemTech has developed much more explicit links with the Longevity industry. The identity of the FemTech sector was boosted by the creation of the Centre for Female Reproductive Longevity and Equality at the Buck Institute for Research on Aging, -- a center for FemTech in all but name.

In July, Nicole Shanahan, a Silicon Valley-based, tech-focused lawyer, entrepreneur, and philanthropist provided a gift of \$6 million in seed money to open a center specifically focused on developing strategies that prevent or delay ovarian aging. The Buck Institute described it as *“the first facility anywhere in the world focused solely on reproductive equality and longevity as it relates to aging and ending the threat of age-related disease.”*

Buck professor Judith Campisi, an expert in cellular senescence and a recurring name in our previous Longevity reports, will lead early recruitment efforts at the center.

Campisi, therefore, stands at the **intersection between FemTech and the Longevity industry** and hopes to bring the full power of the Buck Institute’s 19 labs and research programs in stem cells, cellular stress, and disease, mitochondria and bioenergetics, exercise, nutrition and metabolism for the center.




Judith Campisi, professor of biogerontology at the Buck Institute for Research on Aging, newly elected member of the National Academy of Sciences, and member of the SENS Research Foundation advisory board, is currently leading the recruitment efforts at the world's first center for research into reproductive longevity.

What is the present state of ovarian rejuvenation?

A self-styled “fertility clinic of last resort”, the **Center for Human Reproduction** is a leading fertility center located in New York City.

They currently specialise in “older” ovary rejuvenation, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

“Firsts” developed at CHR included the idea of vaginal egg retrieval, which was performed at CHR for the first time and published in the reputable medical journal The Lancet. CHR investigators also pioneered the concept of tubal catheterization to recanalize obstructed fallopian tubes, first published in the prestigious journal JAMA. The most influential recent contribution of CHR research to infertility treatment was the introduction of supplementation with DHEA in women with poor ovarian reserve.




CHR's physicians and scientists are well recognized by peers all over the world, because of the center's large number of scientific publications and clinical outcomes.

One already available technological means of intervening directly in age-related declining female health is **bioidentical hormone replacement therapy for women**. Women are especially vulnerable to age-related hormonal imbalances such as thyroid disorder, premenstrual syndrome and lowsexual desire.

Hormonal imbalance affects millions of women in the United States. Conditions, such as menopause, thyroid dysfunction, and hypoactive sexual desire disorder (HSDD) are linked to out-of-balance hormones. The symptoms of hormonal imbalance mood swings, insomnia, weight gain and hair loss, women suffering from symptoms of hormone imbalance can find relief can be life-altering:


Hormonal replacement offsets the effects of hormonal imbalance and allows women to experience better health and a higher quality of life when the balance is safely and effectively restored.

Since 2010, more than 10 major medical organizations have come forward to endorse menopausal hormone therapy, heralding it as the best treatment for menopause. Yet, many doctors still sidestep the therapy citing dangerous side effects and risk of disease. This fear began in 2002 when the widely-publicized Women's Health Initiative (WHI) – the largest study ever conducted on the effects of hormone therapy was halted because female subjects were falling ill. The study has since been reviewed and analyzed by experts nationwide, finding that the study's design and methods were faulty and that the use of synthetic hormones—synthetic estrogen and progestin (synthetic progesterone) were largely to blame.



MORE YEARS OF WHAT?

In Europe, men and women are living longer. They are also spending more years with chronic conditions such as diabetes, cancer and Alzheimer's disease.



The rise of the FemTech Longevity sector may partly be the result of the increasing lag between Female healthspan (the number of years free from chronic, degenerative age-related disease) and their rising lifespans.

Females have higher average lifespans and life expectancies than men. However, the number of years spent suffering from age-related diseases like dementia is also higher.

This creates an unmet need for products and services aiming to maximize female healthspan that the rising FemTech Longevity sector is striving to fulfill.

As population aging continues to steepen, and the proportion of individuals above the age of 60 years of age continues to rise, the available market for FemTech Longevity companies rises proportionally.

While the current FemTech Longevity market is dominated by products and services aiming to maintain reproductive and ovarian functionality into middle-age and old-age, we can expect to see an increasing diversity of prognostic, diagnostic and therapeutic applications aiming to intervene upon other forms of female-specific age-related health and wellbeing.

Given the recent increase in the number of FemTech companies focused on a core Longevity component, we predict a rise in the number of FemTech companies focused on Longevity in particular.

Thus far these have tended to concentrate mainly on fertility issues, because longevity in fertility, given the present state of regenerative medicine, is a low hanging fruit and next great step for FemTech. Whereas other aspects of age-related dysfunction in female-specific bodily processes depend on a complex system of tissues and organs - such as menopause-related hormonal imbalances, for example, female age-related infertility for the most part comes down to a decline in the function of specific cells - namely, ovarian cells.

Thus, from a scientific standpoint, therapies aiming to reverse age-related infertility in women can focus on a small subset of cells rather than larger, more complex and interconnected entire bodily tissues, organs and systems, and therefore the barriers to their practical implementation are lower.

Life expectancy by gender



But progress in biomedicine, especially in the use of gene therapies and stem cell therapies to reverse aging in entire biological systems such as the endocrine system, will bring an ever wider range of age-related issues under FemTech’s purview.

We should also expect to see a female-centric healthspan extending sector emerge naturally in the course of the following pursuits:

1. finding geroprotectors that appear to have differential effects in men and women
2. finding interventions (like geroprotectors and gene therapies) that upregulate genes associated with women's higher life expectancy.



AGING ANALYTICS AGENCY

www.aginganalytics.com | info@aginganalytics.com

Aging Analytics Agency is the world's premier Longevity Analytics company, dedicated to the production of industry reports on the topics of Longevity, Precision Preventive medicine and AgeTech. It is the only analytics entity focused exclusively on Ageing, Geroscience and Preventive Medicine. Operating for over five years, it began producing in-depth reports on Longevity long before it emerged as an industry. The company provides strategic consulting in the fields of Longevity and Economics of Aging, and is currently acting as the major source of analytics and data for the UK All-Party Parliamentary Group for Longevity.




**LONGEVITY
INTERNATIONAL**

www.longevity.international | info@longevity.international

Longevity.International is an online interactive database of longevity scientists, companies, and investors. This platform allows different stakeholders in the longevity industry to connect, network, research and analyze.

On the next stage this platform will also employ cutting-edge data visualization software and a networking section where various stakeholders within the longevity industry can connect and collaborate, where longevity companies are matched with the right investors, and where scientists can make contributions.



**DEEP
KNOWLEDGE
ANALYTICS**

www.dka.global | info@dka.global

Deep Knowledge Analytics – the analytical arm of Deep Knowledge Ventures, specialising in forecasting on the convergence of technological megatrends, conducting special case studies and producing advanced industry analytical reports on AI, DeepTech, Blockchain and Invest Tech.



AGING ANALYTICS AGENCY

Aging Analytics Agency (AAA) Disclaimer.

The information and opinions in this report were prepared by Aging Analytics Agency. The information herein is believed by AAA to be reliable but AAA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. AAA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of AAA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of AAA and are subject to change without notice. AAA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.